Interests and perspectives of PET-CT for breast cancer: Review of the literature;Intérêts et perspectives de la TEP-TDM en sénologie: Revue de la littérature

Bulletin du Cancer

Volumn 94, Issue 7-8, 2007, Pages 658-668

  Groheux, David ^a   Hindie, Elif ^a   Espié, Marc ^b   Toubert, Marie Elisabeth ^a   Misset, Jean Louis ^b   Giacchetti, Sylvie ^b   Vercellino, Laetitia ^a   Moretti, Jean Luc ^a  

^a Centre TEP

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

18F fluorodeoxyglucose; Breast cancer; PET CT

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FLUORODEOXYGLUCOSE F 18;

ADVANCED CANCER; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MEDICAL LITERATURE; OSTEOBLAST; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SCINTIGRAPHY; SENSITIVITY ANALYSIS;

BONE NEOPLASMS; BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 34548671218     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0402     Document Type: Review

References (63)

1. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body : metabolism of tumors. London : Constable, 1930.
2. Hatanaka M. Transport of sugar in tumor cell membrannes. Biochim Biophys Acta 1974 ; 355 : 77-104.
3. Rose C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun 2002 ; 23 : 613-8.
4. Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 2004 ; 42 : 1113-22.
5. Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses : comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994 ; 1 : 132-40.
6. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with2-deoxy-2-fluoro-D-glucose PET. Radiology 1993 ; 187 : 743-50.
7. Avril N, Janicke F, Dose J. PET Imaging of breast tumors : Munich experience. J Nucl Med 1995 ; 36 : 82P.
8. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D- glucose-positron emission tomography : clinical evaluation and alternative management. J Natl Cancer Inst 2001 ; 93 : 630-5.
9. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, et al. FDG uptake in breast cancer : correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002 ; 29 : 1317-23.
10. Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2- (fluorine-18)-fluoro-2-deoxy- D-glucose. J Natl Cancer Inst 1996 ; 88 : 1204-9.
11. McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, et al. Positron tomographic assessment of 16 alpha-18F. fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991 ; 32 : 1526-31.
12. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, et al. Positron tomographic assessment of estrogen receptors in breast cancer : comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995 ; 36 : 1766-74.
13. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose : use and limitations. J Clin Oncol 2000 ; 18 : 3495-502.
14. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DH. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors : comparison with long-term clinical outcome. J Nucl Med 2005 ; 46 : 1455-9.
15. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998 ; 28 : 290-302.
16. Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002 ; 75 : 135-46.
17. Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans, et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004 ; 22 : 1253-9.
18. Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH, Oyen WJ. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 2005 ; 92 : 1363-7.
19. Dose J, Bleckmann C, Bachmann S, Bohuslavizki, et al. Comparison of fluorodesoxyglucose positron emission tomography and «conventional diagnostic procedures» for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002 ; 23 : 857-64.
20. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005 ; 32 : 1253-8.
21. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998 ; 39 : 431-5.
22. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol 2005 ; 184 : 1266-73.
23. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. F-18 fluorodesoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma : a comparison to conventional imaging. Invest Radiol 2003 ; 38 : 250-6.
24. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001 ; 42(5 suppl.) : 1S-93S.
25. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer : the referring physician's perspective. J Nucl Med 2001 ; 42 : 1334-7.
26. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol 2004 ; 183 : 479-86.
27. Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN. 18F-FDG in recurrent breast cancer : diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004 ; 31 : 179-88.
28. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006 ; 107 : 2545-51.
29. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005 ; 90 : 105-12.
30. Bourguet P, Hitzel A, Houvenaeghel G, Vinatier D, Bosquet L, Bonichon F, et al. Synthesis bulletin of 2005 surveillance. Clinical practice recommendations : the use of PET-FDG in cancers of the breast, ovary and uterus. Bull Cancer 2006 ; 93 : 385-90.
31. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, et al. Fluorine-18-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer : comparison with the standard staging procedures. Eur J Nucl Med 2001 ; 28 : 351.
32. Heinisch M, Gallowitsch HJ, Mikosch P, Kresnik E, et al. Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. Breast 2003 ; 12 : 17-22.
33. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 2002 ; 9 : 773-83.
34. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma : initial clinical evaluation with PET with the radiolabeled glucose analogue 2-F18-fluoro-2-deoxy-D-glucose. Radiology 1991 ; 179 : 765-70.
35. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992 ; 216 : 27-34.
36. Uno K, Yoshikawa K, Imazeki K, Okada J, Minoshima S, Arimizu N. FDG-PET evaluation of breast cancer : a diagnostic role for primary or metastatic and recurrent lesions. Radiology 1992 : 185-18P.
37. Nieweg OG, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993 ; 71 : 3920-5.
38. Hoh CK, Lee MH, Rege S, Glaspy J, Basset LW, Hawkins RA. Whole-body PET with FDG : a potential complementary technique to mammography for detection of primary, recurrent, and metastatic breast carcinoma. Radiology 1993 ; 189 : 148P.
39. Jacobs M, Mantil J, Peterson C. FDG PET in breast cancer. J Nucl Med 1994 ; 35 : 142P.
40. Jannson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer : a method for early therapy evaluation. J Clin Oncol 1995 ; 13 : 1470-7.
41. Bruce DM, Evans NT, Heys SD, Needham G, BenYounes H, Mikecz P, et al. Positron emission tomography : 2-deoxy-2-18F.-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995 ; 21 : 280-3.
42. Scheidhauer K, Scharl A, Pietrzyk U. Qualitative F-18FDG-PET in breast tumor. Eur J Nucl Med 1995 ; 22 : 734.
43. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997 ; 24 : 1138-45.
44. Hubner KF, Smith GT, Thie JA, Bell JL, Nelson HS, Hanna WT. The potential of F-18FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Positron Imaging 2000 ; 3 : 197-205.
45. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000 ; 24 : 274-80.
46. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004 ; 30 : 15-9.
47. Veronesi U, De Cicco C, Galimberti V, Fernandez J, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007 ; 18 : 473-8.
48. Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003 ; 10 : 622-7.
49. Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004 ; 10 : 89-93.
50. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer : a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004 ; 22 : 277-85.
51. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18- fluorodeoxyglucose in breast cancer. J Nucl Med 1996 ; 37 : 931-8.
52. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Gohring UJ, Schomacker K, et al. Qualitative 18F-FDG positron emission tomography in primary breast cancer : clinical relevance and practicability. Eur J Nucl Med 1996 ; 23 : 618-23.
53. Utech CU, Young CS, Winter PF. Prospective evaluation of fluorine-18-fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996 ; 23 : 1588-93.
54. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, et al. Staging of the axilla in breast cancer : accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D- glucose. Ann Surg 1998 ; 228 : 220-7.
55. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using (18)F.-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000 ; 18 : 1676-88.
56. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response ro neoadjuvant chemotherapy in stage II and III breast cancer by 18F.fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006 ; 24 : 5366-72.
57. Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using 18F.fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006 ; 12: 6437-43.
58. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using (18) F. Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000 ; 18 : 1689-95.
59. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-18F. Fluoro-2-deoxy-D-glucose and 16alpha-18F. fluoro-17beta-estradiol in breast cancer : correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996 ; 2 : 933-9.
60. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using 18F.-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002 ; 38 : 375-9.
61. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of 18F. FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2004 ; 15 : 1352-7.
62. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patienrs. J Nucl Med 2002 ; 43 : 325-9.
63. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by (18)F.2-deoxy-2-fluoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol 2004 ; 130 : 273-8.